Merosin-Deficient CMD Type 1D (MDC1D): LARGE1 Gene Deletion/Duplication

**Test Code:** DLARG
**Turnaround time:** 2 weeks
**CPT Codes:** 81228 x1

### Condition Description

The congenital muscular dystrophies are a group of genetically and clinically heterogeneous hereditary myopathies characterized by congenital hypotonia and muscle weakness, contractures, and delayed motor development. Muscle biopsy usually reveals a nonspecific dystrophic pattern. The clinical course is broadly variable and can involve the brain and eyes. Initial testing often includes clinical evaluation, muscle imaging, electromyography, and muscle biopsy, followed by targeted genetic testing.

A single individual has been recognized with congenital muscular dystrophy type 1D (MDC1D). This individual was 17 years of age at the time of diagnosis and did not have any problems at birth, but was recognized to be developmentally delayed at 5 months of age. She was able to sit unsupported at two and a half years of age, and walked independently at four and a half years of age. Maximal motor function was obtained by nine years of age, after which she gradually worsened. She had contractures at the ankles and elbows, muscle hypertrophy of the quadriceps, calves, and arm muscles, and mild facial weakness.

The affected individual was profoundly mentally retarded with abnormal brain MRI that showed extensive and symmetrical cerebral white matter changes and neuronal migration defects, although brain MRI at age 4 years only showed minimal changes. Serum creatine kinase (CK) levels were elevated 2-20 times normal levels. Muscle biopsy showed uneven reduced staining of alpha dystroglycan, and normal laminin alpha 2 and beta-dystroglycan staining. Two mutations were identified in the LARGE1 gene (22q12.3-q13.1).

For patients with suspected MDC1D, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.

### References


### Genes

**LARGE1**

### Indications

This test is indicated for:

- Confirmation of a clinical diagnosis of MDC1D in an individual in whom sequence analysis was negative
- Carrier testing in adults with a family history of MDC1D in whom sequence analysis was negative

### Methodology

DNA isolated from peripheral blood is hybridized to a CGH array to detect deletions and duplications. The targeted CGH array has overlapping probes which cover the entire genomic region.

Please note that a “backbone” of probes across the entire genome are included on the array for analytical and quality control purposes. Rarely, off-target copy number variants causative of disease may be identified that may or may not be related to the patient’s phenotype. Only known pathogenic off-target copy number variants will be reported. Off-target copy number variants of unknown clinical significance will not be reported.

### Detection

Detection is limited to duplications and deletions. The CGH array will not detect point or intronic mutations.

Results of molecular analysis must be interpreted in the context of the patient's clinical and/or biochemical phenotype.

### Specimen Requirements

Submit only 1 of the following specimen types

* Preferred specimen type: Whole Blood

**Type: Whole Blood**

Specimen Requirements:

In EDTA (purple top) tube:
Infants (2 years): 3-5 ml
Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Type: Saliva**

Specimen Requirements:

Oragene™ Saliva Collection kit (available through EGL) used according to manufacturer instructions.

Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Special Instructions**

Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.

Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.

**Related Tests**

- Sequence analysis of the LARGE1 is required before deletion/duplication analysis
- Prenatal testing is available to couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.